Abstract: PO0589
The Clinical Effect of Paricalcitol Treatment on Hemodialysis Patients with Secondary Hyperparathyroidism and the Influence of Abdominal Aortic Calcification
Session Information
- Vascular Disease, Nephrolithiasis, and Mineral Metabolism: Clinical
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Bone and Mineral Metabolism
- 402 Bone and Mineral Metabolism: Clinical
Authors
- Liu, Yin, Beijing Haidian Hospital, Beijing, China
- Yang, Tao, Beijing Haidian Hospital, Beijing, China
Background
This is an observational study to investigate the clinical efficacy of paricalcitol in maintenance hemodialysis(MHD) patients with secondary hyperparathyroidism(SHPT) and its effect on the level of abdominal aortic calcification(AAC).
Methods
The study included 40 patients (24 males and 16 females) treated with regular MHD with SHPT in the hemodialysis clinic of Beijing Haidian Hospital from April 2019 to June 2020. After 12 weeks treated with Intravenous paricalcitol on the basis of regular hemodialysis, compared the blood calcium, blood phosphorus, and intact parathyroid hormone (iPTH) before and after the treatment and AAC score (Kauppila semi-quantitative method),and observed the clinical efficacy and the level of AAC after treatment with paricalcitol.
Results
Monitored blood calcium, blood phosphorus, and iPTH before starting treatment. Ande after 12 weeks of treatment, monitored blood calcium, blood phosphorus,iPTH, ALP changes and AAC score. The comparison found that the blood phosphorus, iPTH, and ALP levels after treatment were lower than the pre-treatment levels, and the blood calcium was higher than the pre-treatment levels, the difference was statistically significant (P<0.05)(Fig 1). At the same time, it is observed that patients with high levels of iPTH are often accompanied by severe AAC, while patients with mild to moderate AAC often maintain relatively low levels of iPTH. There were differences in the expression levels of iPTH among the three groups of patients with AAC with different conditions, and the differences between the groups were statistically significant (P<0.05)(Fig 2).
Conclusion
Intravenous paricalcitol has a significant effect on SHPT in hemodialysis patients, which can reduce the level of iPTH and reduce the risk of abdominal aortic calcification.
Biochemical indicators before and after treatment
Patient's ACC score and relationship with iPTH level